

Research Article

An HLA-Transgenic Mouse Model of Type 1 Diabetes That Incorporates the Reduced but Not Abolished Thymic Insulin Expression Seen in Patients

Jeffrey Babad,¹ Riyasat Ali,¹ Jennifer Schloss,¹ and Teresa P. DiLorenzo^{1,2}

¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

²Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Correspondence should be addressed to Teresa P. DiLorenzo; teresa.dilorenzo@einstein.yu.edu

Received 5 August 2015; Accepted 4 October 2015

Academic Editor: Roberto Mallone

Copyright © 2016 Jeffrey Babad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of the pancreatic islet beta cells. Multiple genetic loci contribute to disease susceptibility in humans, with the most responsible locus being the major histocompatibility complex (MHC). Certain MHC alleles are predisposing, including the common HLA-A*02:01. After the MHC, the locus conferring the strongest susceptibility to T1D is the regulatory region of the insulin gene, and alleles associated with reduced thymic insulin expression are predisposing. Mice express two insulin genes, *Ins1* and *Ins2*. While both are expressed in beta cells, only *Ins2* is expressed in the thymus. We have developed an HLA-A*02:01-transgenic NOD-based T1D model that is heterozygous for a functional *Ins2* gene. These mice exhibit reduced thymic insulin expression and accelerated disease in both genders. Immune cell populations are not grossly altered, and the mice exhibit typical signs of islet autoimmunity, including CD8 T cell responses to beta cell peptides also targeted in HLA-A*02:01-positive type 1 diabetes patients. This model should find utility as a tool to uncover the mechanisms underlying the association between reduced thymic insulin expression and T1D in humans and aid in preclinical studies to evaluate insulin-targeted immunotherapies for the disease.

1. Introduction

Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of the pancreatic islet beta cells. Multiple genetic loci contribute to T1D susceptibility in humans, with the most responsible locus being the major histocompatibility complex (MHC) [1]. The ability of certain class II MHC genes to influence disease risk has long been appreciated [2, 3]. Multiple studies have also revealed an association with certain class I MHC alleles, including the common HLA-A*02:01 [4–13]. These findings are not surprising, given that CD4 and CD8 T cell responses to a variety of beta cell antigens, including insulin, are observed in T1D patients [14].

After the MHC, the locus that confers the strongest susceptibility to T1D in humans is the variable number of tandem repeats (VNTR) regulatory region of the insulin gene [1, 15]. VNTR alleles with the smallest number of repeats, designated

as class I, predispose to T1D [16, 17], while the longer class III alleles have a dominant protective effect [15, 18]. Class III VNTR alleles are associated with thymic insulin RNA levels that are increased two- to threefold compared to class I alleles [19], leading to the hypothesis that impaired negative selection of insulin-specific T cells in individuals with class I VNTR alleles explains their predisposition to T1D [19, 20]. While findings from a single human study are consistent with this idea [21], the development of a mouse model for T1D that incorporates the reduced, but not abolished, thymic insulin expression observed in patients would allow for more rigorous future testing of this hypothesis.

The NOD mouse is the primary rodent model used for studying T1D [22]. Unlike humans, mice express two insulin genes, *Ins1* and *Ins2*. While both genes are expressed in beta cells [23], *Ins2* expression predominates in the thymus [24–27], with little [24] to no [25–27] detectable thymic *Ins1* expression. *Ins2*-deficient (*Ins2*^{KO}) NOD mice develop

diabetes at an accelerated rate [28–30], as do HLA-A*02:01-transgenic Ins2^{KO} NOD mice [28], and both Ins2-deficient strains have increased insulin-specific islet-infiltrating CD8 T cells compared to their wild-type (WT) counterparts [28]. While these Ins2^{KO} mouse strains highlight the importance of thymic insulin expression, they do not accurately represent a human patient, where thymic insulin expression is diminished but still present [19, 20]. Here we have developed an HLA-A*02:01-transgenic NOD-based T1D model that is heterozygous (het) for the Ins2^{KO} allele, resulting in thymic insulin expression that is decreased but not eliminated. The mice develop accelerated disease compared to Ins2^{WT} mice, and this is true regardless of gender. Immune cell populations are not grossly altered, and the mice exhibit typical signs of islet autoimmunity, including CD8 T cell responses to beta cell peptides also targeted in HLA-A*02:01-positive T1D patients. This model should find utility as a tool to uncover the mechanisms underlying the association between class I VNTR alleles and T1D in humans. It should also aid in preclinical studies to evaluate insulin-targeted immunotherapies for the disease.

2. Materials and Methods

2.1. Mice. NOD. β_2m^{KO} .HHD mice [31] transgenically express a single-chain chimeric HLA-A*02:01 molecule in which human β_2 -microglobulin (β_2m) is covalently linked to the $\alpha 1$ and $\alpha 2$ domains of HLA-A*02:01. The $\alpha 3$, transmembrane, and cytoplasmic portions of the molecule are derived from H-2D^b. Mouse class I MHC molecules are not expressed in these mice due to the murine β_2m deficiency. NOD.Ins2^{KO} mice have been described [29]. The two strains were intercrossed to transfer the Ins2^{KO} allele to the NOD. β_2m^{KO} .HHD strain. The resulting progeny were bred as appropriate to obtain Ins2^{WT} and Ins2^{het} NOD. β_2m^{KO} .HHD mice for our studies. Female β_2m^{KO} mice breed poorly in our hands and so were rarely used for this purpose. Similarly, NOD and NOD.Ins2^{KO} mice were intercrossed and the resulting progeny bred as appropriate to obtain Ins2^{WT} and Ins2^{het} NOD mice. The HHD transgene and the WT and KO β_2m and Ins2 alleles were identified by PCR using the following primer pairs: HHD, 5'-CTTCATCGCAGTGGGCTAC-3' and 5'-CGGTGAGTCTGTGAGTGGG-3'; β_2m^{WT} , 5'-GAAACCCCTCAAATTCAAGTATACTCA-3' and 5'-GACGGTCTTGGGCTCGGCCATACT-3'; β_2m^{KO} , 5'-GAAACCCCTCAAATTCAAGTATACTCA-3' and 5'-TCGAATTGCGCAATGACAAGACGCT-3'; Ins2^{WT}, 5'-GGCAGAGGAGGTGCTTTG-3' and 5'-AGAAAA-CCACCAGGGTAGTTAGC-3'; Ins2^{KO}, 5'-GGCAGAGAGGAGGTGCTTTG-3' and 5'-ATTGACCGTAATGGGATAGG-3'. All animal experiments were approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine.

2.2. Measurement of Thymic Ins2 RNA. Female Ins2^{WT} and Ins2^{het} NOD. β_2m^{KO} .HHD mice (four each) were sacrificed and thymus was harvested. Total thymic RNA was isolated

using the RNeasy Midi Kit (Qiagen, Valencia, CA) and treated with DNase I (Qiagen) to eliminate DNA contamination. 1.5–2.3 μ g of RNA was reverse-transcribed to cDNA using random hexadeoxynucleotides and oligo dT primers (Invitrogen). Equal amounts of cDNA were mixed with SYBR Green PCR Master Mix (Qiagen) and each Ins2 primer (5'-CTTCTTCTACACACCCATGTCC-3' and 5'-TCTACA-ATGCCACGCTTCTG-3') or primers for the U6 normalization control (5'-CTCGCTTCGGCAGCACATATACTA-3' and 5'-ACGAATTTGCGTGTGCATCCTTGCG-3') and brought to a final volume of 25 μ L. Real-time quantitative RT-PCR was performed in triplicate using an iQ5 Optical System (Bio-Rad, Hercules, CA). Amplification was carried out as follows: a single denaturing step at 95°C for 10 min followed by 40 cycles of 95°C for 15 sec, 59°C for 30 sec, and 72°C for 30 sec, followed by a final extension step of 72°C for 3 min. Results were analyzed using the Relative Expression Software Tool (REST) [32, 33].

2.3. Type 1 Diabetes Assessment. Glucosuria was monitored weekly using Diastix reagent strips (Bayer, Elkhart, IN). Mice were considered diabetic after two consecutive positive tests, and the date of the first positive test was recorded as the time of onset of disease.

2.4. Flow Cytometry. Splenocytes from NOD. β_2m^{KO} .HHD and NOD. β_2m^{KO} .HHD.Ins2^{het} mice were analyzed by flow cytometry. Cells were stained with anti-B220, anti-CD11c, anti-CD4, and anti-CD8 (all from BD Biosciences, San Jose, CA). In some samples, cells were stained with anti-CD25 (BD Biosciences), fixed and permeabilized with fixation/permeabilization buffer (eBioscience, San Diego, CA), and stained with anti-Foxp3 (eBioscience).

2.5. Pancreas Histology. To assess insulinitis in female NOD. β_2m^{KO} .HHD and NOD. β_2m^{KO} .HHD.Ins2^{het} mice at 4 and 8 weeks of age, pancreata were fixed in Bouin's solution, embedded in paraffin, and sectioned at nonoverlapping levels. Sections were stained with aldehyde fuchsin to readily visualize granulated beta cells and counterstained with hematoxylin and eosin for detection of leukocytes. Islets were scored as previously described [34]: 0, no insulinitis; 1, local insulinitis without infiltration of islet itself; 2, less than 25% infiltration; 3, 25–75% infiltration; or 4, greater than 75% infiltration. An insulinitis index was calculated by adding the scores of all islets and dividing by four times the number of islets scored. A minimum of 20 islets per mouse were evaluated. Diabetic mice were assigned an insulinitis index of 1.

2.6. Islet Isolation and Culture of Islet-Infiltrating T Cells. Islets were isolated from female NOD. β_2m^{KO} .HHD.Ins2^{het} mice at 8 weeks of age by collagenase P perfusion of the common bile duct as previously described [35]. Islets were handpicked using a micromanipulator and a dissecting microscope and up to 50 islets were transferred per well to




FIGURE 1: Diabetes development in NOD.β₂m^{KO}.HHD and NOD.β₂m^{KO}.HHD.Ins^{het} mice. (a) Female and (b) male NOD.β₂m^{KO}.HHD (filled circles) and NOD.β₂m^{KO}.HHD.Ins^{het} mice (open circles) were followed weekly for diabetes development. (a) $p = 0.0002$, Mantel-Cox. (b) $p = 0.04$, Mantel-Cox.

24-well plates in 500 μL R-10 medium (RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10% FBS, 1 mM sodium pyruvate, 28 μM β-mercaptoethanol, 1x nonessential amino acids (Invitrogen)) with 50 U/mL recombinant human IL-2 (PeproTech, Rocky Hill, NJ). Cells were cultured for 7 days at 37°C in 5% CO₂, at which point the majority of the cells are expected to be CD8 T cells [35].

2.7. IFN-γ ELISPOT Assay. Human HLA-A*02:01-positive T2 cells [36], deficient for the transporter associated with antigen processing, were cultured at 26°C overnight prior to use. ELISPOT plates (Millipore MAHA S4510, Billerica, MA) were coated with anti-mouse IFNγ antibody (BD Biosciences) and blocked with 1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO). T2 cells were plated at 2×10^4 cells/well and pulsed with 10 μM of the indicated peptides for 1 hour at 26°C. Cultured islet-infiltrating T cells from NOD.β₂m^{KO}.HHD.Ins^{het} mice were added at 2×10^4 cells/well in 50 μL R-10. Cells were incubated for 40 hours at 37°C. Wells were then washed with 0.05% Tween 20/PBS and biotinylated anti-mouse IFNγ detection antibody (BD Biosciences) was added for 2 hours at 37°C. After washing, streptavidin-alkaline phosphatase (Zymed Laboratories, Carlsbad, CA) was added and incubated for 1 hour at 37°C. Wells were washed and spots were developed using 5-bromo-4-chloro-3-indolyl-phosphate/nitro-blue tetrazolium substrate (Sigma-Aldrich). Spots were counted using an automated ELISPOT reader system (Autoimmun Diagnostika, Strassberg, Germany). Responses are reported as a stimulation index, which is defined as spot number in response to the test peptide divided by spot number in response to an irrelevant HIV-derived HLA-A*02:01-binding peptide (SLYNTVATL) [37]. The cutoff for positivity is a stimulation index greater than 2 and a test peptide spot number greater than 5 per 1×10^5 T cells [38].

3. Results

3.1. Accelerated Diabetes Development in NOD.β₂m^{KO}.HHD.Ins^{het} Mice. A previous study had demonstrated that Ins^{het} mice of mixed, but primarily C57BL/6, background experience a reduction in thymic insulin expression of approximately 40% [24]. To develop a mouse model of T1D having reduced thymic insulin quantity, and also expressing the human class I MHC molecule HLA-A*02:01, we generated NOD.β₂m^{KO}.HHD.Ins^{het} mice. Using quantitative RT-PCR, we similarly found a reduction in thymic insulin expression of 35% in female Ins^{het} compared to Ins^{WT} mice ($n = 4$ mice of each genotype). Diabetes development in NOD.β₂m^{KO}.HHD.Ins^{het} and NOD.β₂m^{KO}.HHD mice of both genders was then compared. Both female (Figure 1(a)) and male NOD.β₂m^{KO}.HHD.Ins^{het} mice (Figure 1(b)) demonstrated accelerated diabetes development compared to their Ins^{WT} counterparts. Female NOD.β₂m^{KO}.HHD.Ins^{het} mice developed diabetes as early as 9 weeks of age and all were diabetic by 27 weeks (Figure 1(a)). The first onset of diabetes in Ins^{WT} female mice was at 11 weeks, and only 47% developed diabetes by 30 weeks. As also seen in standard NOD males [39, 40], diabetes development was slowed and overall incidence was reduced in NOD.β₂m^{KO}.HHD males (Figure 1(b)) compared to females. However, Ins^{het} males exhibited an earlier onset of disease compared to Ins^{WT} males (10 weeks versus 17 weeks), and a larger percentage (56% versus 24%) had developed diabetes by 30 weeks of age (Figure 1(b)). Thus, both genders of NOD.β₂m^{KO}.HHD.Ins^{het} mice faithfully model the circumstance in humans where reduced thymic insulin expression is predisposing to T1D [16, 17]. Note that this is not what we observed in the case of NOD.Ins^{het} mice, where both female (Figure 2(a)) and male Ins^{het} mice (Figure 2(b)) exhibit a diabetes profile that is statistically indistinguishable from that of NOD mice.




FIGURE 2: Diabetes development in NOD and NOD.Ins2^{het} mice. (a) Female and (b) male NOD (filled circles) and NOD.Ins2^{het} mice (open circles) were followed weekly for diabetes development. (a) $p = 0.63$ (not significant), Mantel-Cox. (b) $p = 0.19$ (not significant), Mantel-Cox.

3.2. Immune Cell Populations Are Not Grossly Altered in NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ Mice. To verify that the accelerated diabetes development observed in NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice could not be attributed to a gross alteration in immune cell populations, we examined the splenocyte composition of 8-week-old female nondiabetic NOD. $\beta_2m^{KO}.HHD$ and NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice (Figure 3(a)). It was previously shown that NOD. $\beta_2m^{KO}.HHD$ mice have a reduced CD8 T cell population and elevated B and CD4 T cells compared to standard NOD mice [31]. This was also true for NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice, and no differences were observed in any of the cell types analyzed as a percentage of total cells. To investigate whether a reduction in regulatory T cells (T_{reg}) might contribute to disease pathogenesis in the $Ins2^{het}$ mice, NOD. $\beta_2m^{KO}.HHD$ and NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ splenocytes were monitored for expression of the characteristic T_{reg} cell phenotype, $CD4^+CD25^+Foxp3^+$. No difference was observed in T_{reg} cells as a percentage of CD4 T cells (Figure 3(b)). These results indicate that the accelerated diabetes development seen in NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice is the result of neither an altered immune cell composition nor reduced T_{reg} cells, at least at the level investigated here, that is, without regard to antigenic specificity.

3.3. NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ Mice Exhibit Typical Signs of Islet Autoimmunity. In mixed background mice carrying zero, one, or two copies of the *Ins2* gene, pancreatic insulin content is indistinguishable [24]. Furthermore, $Ins2^{KO}$ mice perform identically to their $Ins2^{WT}$ counterparts in intraperitoneal glucose tolerance tests [41]. Thus, we hypothesized that the diabetes observed in NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice was of an autoimmune nature, as is the case for the NOD. $\beta_2m^{KO}.HHD$ parent strain [31], and not a deficiency in pancreatic insulin production due to the presence of

only one functional copy of the *Ins2* gene. To verify this, histological sections of pancreata from female mice at 4 and 8 weeks of age were examined. All mice studied exhibited some degree of insulinitis, which progressed significantly with age (Figure 3(c)), and islets showing a wide range of immune cell infiltration and beta cell destruction were observed (Figure 3(c)).

We previously identified several HLA-A*02:01-restricted beta cell epitopes, derived from the autoantigens insulin and islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) that are recognized by islet-infiltrating T cells from NOD. $\beta_2m^{KO}.HHD$ mice [31, 42]. To further confirm the autoimmune nature of the diabetes observed in NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice, islets from 8-week-old females were cultured for 7 days and T cell reactivity to the previously identified beta cell epitopes was monitored by IFN γ ELISPOT. All mice harbored autoreactive T cells specific for at least two epitopes (Figure 3(d)), further confirming the autoimmune nature of their disease. A subset of these epitopes (Ins B5–14, IGRP 228–236, and IGRP 265–273) have previously been shown to be recognized by CD8 T cells in HLA-A*02:01-positive T1D patients [43–46], supporting the clinical relevance of the model.

4. Discussion

Insulin is an important autoantigen recognized by T cells in both human T1D and the NOD mouse model of the disease [47]. Reduced thymic insulin expression is associated with susceptibility to T1D in patients [16, 17, 19, 20], suggesting that impaired negative selection of T cells specific for insulin is responsible for this predisposition. Here we have developed and characterized NOD. $\beta_2m^{KO}.HHD.Ins2^{het}$ mice as a model of T1D that incorporates reduced thymic insulin. We find that, as in patients, disease is accelerated (Figure 1), and we suggest these mice as a new diabetes model




FIGURE 3: Splenocyte composition, insulinitis, and autoreactive CD8 T cell specificities in NOD. β_2m^{KO} .HHD.Ins2^{het} mice. (a) and (b) Splenocytes from 8-week-old female NOD. β_2m^{KO} .HHD (filled circles) and NOD. β_2m^{KO} .HHD.Ins2^{het} mice (open circles) were analyzed by flow cytometry. Each symbol represents an individual mouse. (c) Female NOD. β_2m^{KO} .HHD (filled circles) and NOD. β_2m^{KO} .HHD.Ins2^{het} mice (open circles) were sacrificed at 4 and 8 weeks of age and insulinitis indices were determined as described in Materials and Methods and plotted. Each symbol represents an individual mouse. * $p = 0.0037$ (Mann-Whitney U). Representative islets from a single NOD. β_2m^{KO} .HHD.Ins2^{het} mouse are also shown. In these images, beta cells appear dark purple and are denoted by red arrows, while the more lightly stained infiltrating immune cells are marked by black arrows. The number on each image indicates the insulinitis score of the islet shown. (d) Islet-infiltrating cells from 8-week-old female NOD. β_2m^{KO} .HHD.Ins2^{het} mice were tested for reactivity to the indicated HLA-A*02:01-restricted insulin and IGRP epitopes by IFN- γ ELISPOT. Stimulation index was calculated by dividing the number of spots detected for a given peptide by the number of spots detected with an irrelevant HIV-derived HLA-A*02:01-binding peptide. A stimulation index greater than 2 was considered a positive response.

that can be used to better understand this phenomenon. The NOD. β_2m^{KO} .HHD.Ins2^{het} mice present advantages over other disease models that have been described for this purpose. For example, thymic insulin expression is abolished in NOD.Ins2^{KO} and NOD. β_2m^{KO} .HHD.Ins2^{KO} mice, and both exhibit accelerated T1D [28–30] and increased

insulin-specific islet-infiltrating CD8 T cells [28] when compared to their Ins2^{WT} counterparts. While these findings suggest the importance of thymic insulin expression, Ins2^{KO} models do not accurately represent patients, where thymic insulin expression is reduced, but not eliminated [19, 20]. As for NOD.Ins2^{het} mice, in our hands neither females

nor males show accelerated disease (Figure 2). Two earlier studies of NOD. β_2m^{het} mice also showed no effect on disease in males [29, 30], and only one of the two showed acceleration in females [29]. In contrast, both male and female NOD. β_2m^{KO} .HHD. β_2m^{het} mice show enhanced disease (Figure 1). Indeed, the female and male incidence curves are nearly overlapping until 15 weeks of age (cf. Figures 1(a) and 1(b)). Thus, future mechanistic studies could realistically be performed using both genders. These studies should include the quantification of insulin-specific effector T cells and T_{reg} and analysis of their phenotype and function. The recently described ability to isolate insulin-specific CD4 T cells from NOD mouse strains using enrichment with peptide/MHC tetramer reagents will facilitate this work [48].

In NOD mice, establishment of immunological tolerance to insulin can lead to prevention of T1D [49–51] and remission of established disease [52]. Because of these findings, there is great interest in immunological interventions for human T1D that seek to manipulate the T cell response to insulin [53]. The NOD. β_2m^{KO} .HHD. β_2m^{het} mouse strain should be considered as an additional preclinical model to be used to evaluate such therapies, as it incorporates aspects of the human disease that are not represented in standard NOD mice, including reduced thymic insulin expression. In humans, VNTR alleles associated with diminished thymic insulin have been shown to alter the frequency and avidity of insulin-specific T cells [21], both of which could reasonably influence the outcome of therapies designed to manipulate the immune response to insulin. Given that human insulin-specific CD8 T cells have been shown to have cytotoxic activity against islets [54], an additional advantage of the NOD. β_2m^{KO} .HHD. β_2m^{het} mouse model is the expression of the T1D-predisposing human class I MHC allele HLA-A*02:01 [4, 6, 8, 12], which we have shown as supporting the development of T cells specific for HLA-A*02:01-restricted insulin epitopes in these mice (Figure 3(d)). In terms of insulin-specific CD4 T cells, the class II MHC allele expressed in the NOD. β_2m^{KO} .HHD. β_2m^{het} mice is I-A^{G7}, which is structurally similar to the human T1D-predisposing HLA-DQ8 [55, 56]. Indeed, I-A^{G7} and HLA-DQ8 are capable of presenting similar peptides [57–59]. The NOD. β_2m^{KO} .HHD. β_2m^{het} mouse therefore has a variety of potential uses as a humanized model of T1D, including CD8 and CD4 T cell epitope identification, analysis of the relationship between thymic insulin expression and tolerance, and the evaluation of antigen-specific immunotherapies, particularly those targeting the immune response to insulin.

5. Conclusions

NOD. β_2m^{KO} .HHD. β_2m^{het} mice represent a model for T1D that incorporates the reduced, but not abolished, thymic insulin expression observed in patients. This model should find utility in investigations to probe the mechanisms underlying the association between reduced thymic insulin expression and T1D in humans. It will also be an important tool for T cell epitope discovery and for the preclinical evaluation of insulin-targeted immunotherapies for the disease.

Ethical Approval

All animal experiments were approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by the National Institutes of Health (R01 DK094327, R01 DK064315, and R03 AI119225 to Teresa P. DiLorenzo; T32 GM007288 and F30 DK103368, which supported Jennifer Schloss; P60 DK020541, which supports the Diabetes Research Center of the Albert Einstein College of Medicine; and P30 CA013330, which supports the flow cytometry facility). Teresa P. DiLorenzo is the Diane Belfer, Cypres and Endelson Families Faculty Scholar in Diabetes Research.

References

- [1] F. Pociot, B. Akolkar, P. Concannon et al., “Genetics of type 1 diabetes: what’s next?” *Diabetes*, vol. 59, no. 7, pp. 1561–1571, 2010.
- [2] F. Cucca, R. Lampis, M. Congia et al., “A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins,” *Human Molecular Genetics*, vol. 10, no. 19, pp. 2025–2037, 2001.
- [3] J. A. Todd, J. I. Bell, and H. O. McDevitt, “HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus,” *Nature*, vol. 329, no. 6140, pp. 599–604, 1987.
- [4] M. Fennessy, K. Metcalfe, G. A. Hitman et al., “A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population,” *Diabetologia*, vol. 37, no. 9, pp. 937–944, 1994.
- [5] M. C. Honeyman, L. C. Harrison, B. Drummond, P. G. Colman, and B. D. Tait, “Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease,” *Molecular Medicine*, vol. 1, no. 5, pp. 576–582, 1995.
- [6] J. M. M. Howson, N. M. Walker, D. Clayton, and J. A. Todd, “Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A,” *Diabetes, Obesity and Metabolism*, vol. 11, supplement 1, pp. 31–45, 2009.
- [7] K. Nakanishi, T. Kobayashi, T. Murase, T. Naruse, Y. Nose, and H. Inoko, “Human leukocyte antigen-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of β -cell destruction,” *Journal of Clinical Endocrinology and Metabolism*, vol. 84, no. 10, pp. 3721–3725, 1999.
- [8] S. Nejentsev, J. M. Howson, N. M. Walker et al., “Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A,” *Nature*, vol. 450, no. 7171, pp. 887–892, 2007.

- [9] S. Nejentsev, H. Reijonen, B. Adojaan et al., "The effect of HLA-B allele on the IDDM risk defined by DRB1*04 subtypes and DQB1*0302," *Diabetes*, vol. 46, no. 11, pp. 1888–1892, 1997.
- [10] J. A. Noble, A. M. Valdes, T. L. Bugawan, R. J. Apple, G. Thomson, and H. A. Erlich, "The HLA class I A locus affects susceptibility to type 1 diabetes," *Human Immunology*, vol. 63, no. 8, pp. 657–664, 2002.
- [11] J. A. Noble, A. M. Valdes, M. D. Varney et al., "HLA class I and genetic susceptibility to type 1 diabetes: results from the type 1 diabetes genetics consortium," *Diabetes*, vol. 59, no. 11, pp. 2972–2979, 2010.
- [12] D. T. Robles, G. S. Eisenbarth, T. Wang et al., "Identification of children with early onset and high incidence of anti-islet autoantibodies," *Clinical Immunology*, vol. 102, no. 3, pp. 217–224, 2002.
- [13] B. D. Tait, P. G. Colman, G. Morahan et al., "HLA genes associated with autoimmunity and progression to disease in type 1 diabetes," *Tissue Antigens*, vol. 61, no. 2, pp. 146–153, 2003.
- [14] T. P. Di Lorenzo, M. Peakman, and B. O. Roep, "Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes," *Clinical & Experimental Immunology*, vol. 148, no. 1, pp. 1–16, 2007.
- [15] S. T. Bennett, A. M. Lucassen, S. C. L. Gough et al., "Susceptibility to human type 1 diabetes at *IDDM2* is determined by tandem repeat variation at the insulin gene minisatellite locus," *Nature Genetics*, vol. 9, no. 3, pp. 284–292, 1995.
- [16] G. I. Bell, S. Horita, and J. H. Karam, "A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus," *Diabetes*, vol. 33, no. 2, pp. 176–183, 1984.
- [17] G. A. Hitman, A. C. Tarn, R. M. Winter et al., "Type 1 (insulin-dependent) diabetes and a highly variable locus close to the insulin gene on chromosome 11," *Diabetologia*, vol. 28, no. 4, pp. 218–222, 1985.
- [18] S. T. Bennett, A. J. Wilson, F. Cucca et al., "*IDDM2*-*VNTR*-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus," *Journal of Autoimmunity*, vol. 9, no. 3, pp. 415–421, 1996.
- [19] P. Vafiadis, S. T. Bennett, J. A. Todd et al., "Insulin expression in human thymus is modulated by *INS* VNTR alleles at the *IDDM2* locus," *Nature Genetics*, vol. 15, no. 3, pp. 289–292, 1997.
- [20] A. Pugliese, M. Zeller, A. Fernandez Jr. et al., "The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the *INS* VNTR-*IDDM2* susceptibility locus for type 1 diabetes," *Nature Genetics*, vol. 15, no. 3, pp. 293–297, 1997.
- [21] I. Durinovic-Belló, R. P. Wu, V. H. Gersuk, S. Sanda, H. G. Shilling, and G. T. Nepom, "Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin," *Genes and Immunity*, vol. 11, no. 2, pp. 188–193, 2010.
- [22] J. P. Driver, D. V. Serreze, and Y.-G. Chen, "Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease," *Seminars in Immunopathology*, vol. 33, no. 1, pp. 67–87, 2011.
- [23] B. M. Wentworth, I. M. Schaefer, L. Villa-Komaroff, and J. M. Chirgwin, "Characterization of the two nonallelic genes encoding mouse preproinsulin," *Journal of Molecular Evolution*, vol. 23, no. 4, pp. 305–312, 1986.
- [24] A. A. Chentoufi and C. Polychronakos, "Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the *IDDM2* locus may predispose to diabetes," *Diabetes*, vol. 51, no. 5, pp. 1383–1390, 2002.
- [25] V. L. Heath, N. C. Moore, S. M. Parnell, and D. W. Mason, "Intrathymic expression of genes involved in organ specific autoimmune disease," *Journal of Autoimmunity*, vol. 11, no. 4, pp. 309–318, 1998.
- [26] M. Nakayama, N. Babaya, D. Miao, K. Sikora, J. F. Elliott, and G. S. Eisenbarth, "Thymic expression of mutated B16: a preproinsulin messenger RNA does not reverse acceleration of NOD diabetes associated with insulin 2 (thymic expressed insulin) knockout," *Journal of Autoimmunity*, vol. 25, no. 3, pp. 193–198, 2005.
- [27] J.-M. Pléau, A. Esling, S. Geutkens, M. Dardenne, and F. Homodelarche, "Pancreatic hormone and glutamic acid decarboxylase expression in the mouse thymus: a real-time PCR study," *Biochemical and Biophysical Research Communications*, vol. 283, no. 4, pp. 843–848, 2001.
- [28] I. Jarchum and T. P. DiLorenzo, "*Ins2* deficiency augments spontaneous HLA-A*0201-restricted T cell responses to insulin," *Journal of Immunology*, vol. 185, no. 2, pp. 658–665, 2010.
- [29] H. Moriyama, N. Abiru, J. Paronen et al., "Evidence for a primary islet autoantigen (preproinsulin 1) for insulinitis and diabetes in the nonobese diabetic mouse," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 18, pp. 10376–10381, 2003.
- [30] K. Thébault-Baumont, D. Dubois-Laforgue, P. Krief et al., "Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice," *The Journal of Clinical Investigation*, vol. 111, no. 6, pp. 851–857, 2003.
- [31] T. Takaki, M. P. Marron, C. E. Mathews et al., "HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes," *The Journal of Immunology*, vol. 176, no. 5, pp. 3257–3265, 2006.
- [32] M. W. Pfaffl, "A new mathematical model for relative quantification in real-time RT-PCR," *Nucleic Acids Research*, vol. 29, no. 9, article e45, 2001.
- [33] M. W. Pfaffl, G. W. Horgan, and L. Dempfle, "Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR," *Nucleic Acids Research*, vol. 30, no. 9, article e36, 2002.
- [34] D. V. Serreze, H. D. Chapman, D. S. Varnum et al., "B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Igμ(null) mice," *Journal of Experimental Medicine*, vol. 184, no. 5, pp. 2049–2053, 1996.
- [35] I. Jarchum, T. Takaki, and T. P. DiLorenzo, "Efficient culture of CD8⁺ T cells from the islets of NOD mice and their use for the study of autoreactive specificities," *Journal of Immunological Methods*, vol. 339, no. 1, pp. 66–73, 2008.
- [36] R. D. Salter, D. N. Howell, and P. Cresswell, "Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids," *Immunogenetics*, vol. 21, no. 3, pp. 235–246, 1985.
- [37] T. J. Tsomides, A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen, "Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1," *Journal of Experimental Medicine*, vol. 180, no. 4, pp. 1283–1293, 1994.
- [38] Z. Moodie, L. Price, C. Gouttfeangeas et al., "Response definition criteria for ELISPOT assays revisited," *Cancer Immunology, Immunotherapy*, vol. 59, no. 10, pp. 1489–1501, 2010.
- [39] J. G. M. Markle, D. N. Frank, S. Mortin-Toth et al., "Sex differences in the gut microbiome drive hormone-dependent

- regulation of autoimmunity," *Science*, vol. 339, no. 6123, pp. 1084–1088, 2013.
- [40] P. Pozzilli, A. Signore, A. J. K. Williams, and P. E. Beales, "NOD mouse colonies around the world—recent facts and figures," *Immunology Today*, vol. 14, no. 5, pp. 193–196, 1993.
- [41] L. Leroux, P. Desbois, L. Lamotte et al., "Compensatory responses in mice carrying a null mutation for *Ins1* or *Ins2*," *Diabetes*, vol. 50, supplement 1, pp. S150–S153, 2001.
- [42] I. Jarchum, J. C. Baker, T. Yamada et al., "In vivo cytotoxicity of insulin-specific CD8⁺ T-cells in HLA-A*0201 transgenic NOD mice," *Diabetes*, vol. 56, no. 10, pp. 2551–2560, 2007.
- [43] E. Énée, E. Martinuzzi, P. Blancou, J.-M. Bach, R. Mallone, and P. V. Endert, "Equivalent specificity of peripheral blood and islet-infiltrating CD8⁺ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice," *Journal of Immunology*, vol. 180, no. 8, pp. 5430–5438, 2008.
- [44] I. Jarchum, L. Nichol, M. Trucco, P. Santamaria, and T. P. DiLorenzo, "Identification of novel IGRP epitopes targeted in type 1 diabetes patients," *Clinical Immunology*, vol. 127, no. 3, pp. 359–365, 2008.
- [45] R. Mallone, E. Martinuzzi, P. Blancou et al., "CD8⁺ T-cell responses identify β -cell autoimmunity in human type 1 diabetes," *Diabetes*, vol. 56, no. 3, pp. 613–621, 2007.
- [46] W. W. J. Unger, T. Pearson, J. R. F. Abreu et al., "Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice," *PLoS ONE*, vol. 7, no. 11, Article ID e49213, 2012.
- [47] M. Nakayama, "Insulin as a key autoantigen in the development of type 1 diabetes," *Diabetes/Metabolism Research and Reviews*, vol. 27, no. 8, pp. 773–777, 2011.
- [48] K. E. Pauken, J. L. Linehan, J. A. Spanier et al., "Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice," *Journal of Immunology*, vol. 191, no. 10, pp. 4913–4917, 2013.
- [49] M. B. French, J. Allison, D. S. Cram et al., "Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice," *Diabetes*, vol. 46, no. 1, pp. 34–39, 1997.
- [50] E. Jaeckel, M. A. Lipes, and H. von Boehmer, "Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes," *Nature Immunology*, vol. 5, no. 10, pp. 1028–1035, 2004.
- [51] B. Krishnamurthy, N. L. Dudek, M. D. McKenzie et al., "Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP," *Journal of Clinical Investigation*, vol. 116, no. 12, pp. 3258–3265, 2006.
- [52] B. T. Fife, I. Guleria, M. Gubbels Bupp et al., "Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway," *Journal of Experimental Medicine*, vol. 203, no. 12, pp. 2737–2747, 2006.
- [53] L. C. Harrison, J. M. Wentworth, Y. Zhang et al., "Antigen-based vaccination and prevention of type 1 diabetes," *Current Diabetes Reports*, vol. 13, no. 5, pp. 616–623, 2013.
- [54] D. Kronenberg, R. R. Knight, M. Estorninho et al., "Circulating proinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β -cells," *Diabetes*, vol. 61, no. 7, pp. 1752–1759, 2012.
- [55] A. L. Corper, T. Stratmann, V. Apostolopoulos et al., "A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes," *Science*, vol. 288, no. 5465, pp. 505–511, 2000.
- [56] K. H. Lee, K. W. Wucherpfennig, and D. C. Wiley, "Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes," *Nature Immunology*, vol. 2, no. 6, pp. 501–507, 2001.
- [57] M. Nakayama, K. McDaniel, L. Fitzgerald-Miller et al., "Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 14, pp. 4429–4434, 2015.
- [58] A. Suri, J. J. Walters, M. L. Gross, and E. R. Unanue, "Natural peptides selected by diabetogenic DQ8 and murine I-A^{g7} molecules show common sequence specificity," *Journal of Clinical Investigation*, vol. 115, no. 8, pp. 2268–2276, 2005.
- [59] L. Wen, F. S. Wong, R. Sherwin, and C. Mora, "Human DQ8 can substitute for murine I-A^{g7} in the selection of diabetogenic T cells restricted to I-A^{g7}," *The Journal of Immunology*, vol. 168, no. 7, pp. 3635–3640, 2002.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

